Immunogenicity and protective efficacy of a prototype Campylobacter killed whole-cell vaccine in mice (original) (raw)

Abstract

The immunogenicity and efficacy of an experimental inactivated Campylobacter jejuni whole-cell (CWC) vaccine were evaluated in mice. Mice were orally immunized in a three-dose primary series (48-h intervals) at doses of 10(5), 10(7), or 10(9) CWC vaccine particles alone or in combination with 25 micrograms of a mucosal adjuvant, the heat-labile enterotoxin of Escherichia coli (LT). The comparative immunogenicities of both formulations were assessed on the basis of the generation of antigen-specific antibodies in serum and intestinal secretions, and efficacy was determined by measuring the degrees of protection afforded against intestinal colonization and systemic dissemination of challenge organisms. Campylobacter-specific intestinal immunoglobulin (Ig) A responses were dependent on the use of LT, whereas IgA and IgG responses in serum were not. Colonization resistance was induced over a broad range of vaccine doses when LT was included. However, only the highest dose of CWC alone gave comparable levels of protection. Both formulations provided equivalent protection against systemic spread of challenge organisms. These results indicate that both whole-cell vaccine formulations deserve further evaluation as candidate vaccines and also highlight the potential value of mucosal adjuvants, like LT, in enteric vaccine development.

Full Text

The Full Text of this article is available as a PDF (225.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baqar S., Bourgeois A. L., Schultheiss P. J., Walker R. I., Rollins D. M., Haberberger R. L., Pavlovskis O. R. Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates. Vaccine. 1995 Jan;13(1):22–28. doi: 10.1016/0264-410x(95)80006-y. [DOI] [PubMed] [Google Scholar]
  2. Baqar S., Pacheco N. D., Rollwagen F. M. Modulation of mucosal immunity against Campylobacter jejuni by orally administered cytokines. Antimicrob Agents Chemother. 1993 Dec;37(12):2688–2692. doi: 10.1128/aac.37.12.2688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Black R. E., Levine M. M., Clements M. L., Hughes T. P., Blaser M. J. Experimental Campylobacter jejuni infection in humans. J Infect Dis. 1988 Mar;157(3):472–479. doi: 10.1093/infdis/157.3.472. [DOI] [PubMed] [Google Scholar]
  4. Blaser M. J., Black R. E., Duncan D. J., Amer J. Campylobacter jejuni-specific serum antibodies are elevated in healthy Bangladeshi children. J Clin Microbiol. 1985 Feb;21(2):164–167. doi: 10.1128/jcm.21.2.164-167.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Blaser M. J., Duncan D. J., Osterholm M. T., Istre G. R., Wang W. L. Serologic study of two clusters of infection due to Campylobacter jejuni. J Infect Dis. 1983 May;147(5):820–823. doi: 10.1093/infdis/147.5.820. [DOI] [PubMed] [Google Scholar]
  6. Cárdenas L., Dasgupta U., Clements J. D. Influence of strain viability and antigen dose on the use of attenuated mutants of Salmonella as vaccine carriers. Vaccine. 1994 Jul;12(9):833–840. doi: 10.1016/0264-410x(94)90293-3. [DOI] [PubMed] [Google Scholar]
  7. Dickinson B. L., Clements J. D. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun. 1995 May;63(5):1617–1623. doi: 10.1128/iai.63.5.1617-1623.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Holmgren J., Svennerholm A. M. Development of oral vaccines against cholera and enterotoxinogenic Escherichia coli diarrhea. Scand J Infect Dis Suppl. 1990;76:47–53. [PubMed] [Google Scholar]
  9. Jian-Xin G., Huan-Niu W., Gen-Fu X. Studies on intestinal mucosal immunity in mice orally immunized with killed Campylobacter jejuni. Adv Exp Med Biol. 1987;216B:1863–1875. [PubMed] [Google Scholar]
  10. Johnson R. J., Nolan C., Wang S. P., Shelton W. R., Blaser M. J. Persistent Campylobacter jejuni infection in an immunocompromised patient. Ann Intern Med. 1984 Jun;100(6):832–834. doi: 10.7326/0003-4819-100-6-832. [DOI] [PubMed] [Google Scholar]
  11. McSweegan E., Burr D. H., Walker R. I. Intestinal mucus gel and secretory antibody are barriers to Campylobacter jejuni adherence to INT 407 cells. Infect Immun. 1987 Jun;55(6):1431–1435. doi: 10.1128/iai.55.6.1431-1435.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pavlovskis O. R., Rollins D. M., Haberberger R. L., Jr, Green A. E., Habash L., Strocko S., Walker R. I. Significance of flagella in colonization resistance of rabbits immunized with Campylobacter spp. Infect Immun. 1991 Jul;59(7):2259–2264. doi: 10.1128/iai.59.7.2259-2264.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Quiding M., Nordström I., Kilander A., Andersson G., Hanson L. A., Holmgren J., Czerkinsky C. Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory. J Clin Invest. 1991 Jul;88(1):143–148. doi: 10.1172/JCI115270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Rollwagen F. M., Pacheco N. D., Clements J. D., Pavlovskis O., Rollins D. M., Walker R. I. Killed Campylobacter elicits immune response and protection when administered with an oral adjuvant. Vaccine. 1993 Oct;11(13):1316–1320. doi: 10.1016/0264-410x(93)90101-3. [DOI] [PubMed] [Google Scholar]
  15. Sanchez J. L., Vasquez B., Begue R. E., Meza R., Castellares G., Cabezas C., Watts D. M., Svennerholm A. M., Sadoff J. C., Taylor D. N. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet. 1994 Nov 5;344(8932):1273–1276. doi: 10.1016/s0140-6736(94)90755-2. [DOI] [PubMed] [Google Scholar]
  16. Sollid L. M., Kvale D., Brandtzaeg P., Markussen G., Thorsby E. Interferon-gamma enhances expression of secretory component, the epithelial receptor for polymeric immunoglobulins. J Immunol. 1987 Jun 15;138(12):4303–4306. [PubMed] [Google Scholar]
  17. Walker R. I. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine. 1994 Apr;12(5):387–400. doi: 10.1016/0264-410x(94)90112-0. [DOI] [PubMed] [Google Scholar]
  18. Walker R. I., Schmauder-Chock E. A., Parker J. L., Burr D. Selective association and transport of Campylobacter jejuni through M cells of rabbit Peyer's patches. Can J Microbiol. 1988 Oct;34(10):1142–1147. doi: 10.1139/m88-201. [DOI] [PubMed] [Google Scholar]
  19. Wennerås C., Svennerholm A. M., Ahrén C., Czerkinsky C. Antibody-secreting cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine. Infect Immun. 1992 Jul;60(7):2605–2611. doi: 10.1128/iai.60.7.2605-2611.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wennerås C., Svennerholm A. M., Czerkinsky C. Vaccine-specific T cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine. Infect Immun. 1994 Mar;62(3):874–879. doi: 10.1128/iai.62.3.874-879.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]